Understanding Imfinzi treatment for your patients with non-small cell lung cancer (NSCLC)
Please click the links above or the images below to download resources and view support materials to help manage patients taking Imfinzi.
About Imfinzi
Would you like to receive updated Imfinzi resources or information on AstraZeneca Oncology products?
Be IN the know with Imfinzi’s PACIFIC OS data
Nurse Kit Resources
imAR Handbook
High-level details concerning imAEs, how to recognize them, and how to manage them.
imAR Checklist
A concise checklist that allows you to run through potential imARs during your patient consultation.
Pocket Guide
A tool that you can carry with you at all times that provides an overview of imAEs and their management.
GP/Pharmacist ImAR Letter
To give to pharmacists and healthcare professionals in your centre/clinic so they can better understand the patient’s treatment and how to manage their potential side effects.
Patient Side Effects Tracker
Tear Pad
A tool for your patients to track and communicate their side effects in a clear and comprehensive table.
PACIFIC: Primary OS analysis
(full analysis set; median duration of follow-up 25.2 [0.2–43.1] months [all patients])1,2*
Imfinzi DEMONSTRATED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN OS VS. PLACEBO1 Imfinzi demonstrated a statistically significant and clinically meaningful improvement in OS vs. placebo (HR: 0.68; 95% CI: 0.53, 0.87; p=0.00251); 183/476 (38.4%) events with Imfinzi vs. 116/237 (48.9%) events with placebo1
See study parameters below.‖
Adapted from Imfinzi Product Monograph.1
CI, confidence interval; HR, hazard ratio; mOS, median overall survival.
* Compared with allocated α of 0.00274 (Lan DeMets spending function approximating O’Brien Fleming boundary) for interim analysis. † Compared with α of 0.05 following statistically significant progression-free survival and OS at interim analyses.
Consider Imfinzi: The only immunotherapy available for the treatment of patients with locally advanced, stage III, unresectable NSCLC without disease progression following platinum-based CRT.‡
CRT, chemoradiation therapy.
‡ Comparative clinical significance is unknown.
PACIFIC: 5-year updated OS analysis
(planned exploratory analysis; median duration of follow-up of 34.2 [0.2–74.7] months [all patients], 61.6 [0.4–74.7] months [censored patients])3§
OS DATA WITH ImfinziVS. PLACEBO3
See study parameters below. ‖
See study parameters below.‖
Adapted from Spigel DR, et al. 2022.3
CI, confidence interval; HR, hazard ratio; mOS, median overall survival.
§ Not formally statistically tested.
Click here to download the full study and learn more.
‖ PACIFIC was a randomized, double-blind, placebo-controlled, multicentre Phase III study comparing Imfinzi vs. placebo in patients with locally advanced, Stage III, unresectable NSCLC with no disease progression after platinum-based CRT. Patients with World Health Organization performance status 0 or 1 (any tumour programmed cell death-ligand 1 status) were randomly assigned (2:1) to Imfinzi (10 mg/kg IV Q2W for 12 months) or placebo, stratified by age, sex, and smoking history. Time-to-event end point analyses were performed using stratified log-rank tests. Medians and landmark survival rates were estimated using the Kaplan-Meier method. The primary analyses of OS and progression-free survival (RECIST v1.1; assessed by blinded independent central review [BICR]) with Imfinzi vs. placebo was updated in the intent-to-treat population approximately 5 years after the last patient was randomized.3
Overall, 34 of 476 (7.1%) patients in the durvalumab arm received retreatment. Retreatment is not recommended. The recommended dose of Imfinzi is 10 mg/kg Q2W or 1,500 mg Q4W, which should continue for one year or until disease progression or unacceptable toxicity.1,3
CRT, chemoradiation therapy; Q2W, every other week; Q4W, every 4 weeks.
PACIFIC Trail Paper
Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342-2350.
Reprint of the pivotal PACIFIC trial overall survival results, as published in the New England Journal of Medicine.
PACIFIC Postcard
Overview of the IMFINZI indication and its use in the PACIFIC Regimen.
For Patients
IMFINZI Note Card
A small card for patients to take notes when discussing their IMFINZI treatment plan.
Chemoradiation Therapy Postcard
An overview of the definitive platinum-based concurrent chemoradiation therapy (cCRT) regimens received by patients prior to their enrollment in the PACIFIC Study.
Clinical Efficacy and Dosing Guide
A review of IMFINZI clinical efficacy results from the PACIFIC trial, and recommended dosing and administration with adjustment guidance.
Loading......
HCP Resources
PACIFIC 5-Year Updated Exploratory OS Analysis Publication
NSCLC
Imfinzi's 5-year updated exploratory OS data in Stage III, unresectable NSCLC patients who have not progressed post-CRT.
Spigel DR, Faivre-Finn C, et al. Five-Year Survival Outcomes from the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. J Clin Oncol. 2022; 40(12): 1301-1311.
PACIFIC OS Data Summary
NSCLC
An overview of the primary and 5-year updated exploratory OS data.
Dosing Guide
NSCLC
A guide for Imfinzi’s recommended dosage, dosage adjustments, and administration.
-Handbook-Thumbnail.png)
-Handbook-Thumbnail-mob.png)
Immune-Mediated Adverse Reactions (imARs) Handbook
NSCLC
A guide for recognizing and managing imARs associated with Imfinzi.
Imfinzi Product Monograph
NSCLC
Complete details on Imfinzi’s properties, indications, dosing, contraindications, warnings, adverse events, and clinical pharmacology.
CRT, chemoradiation therapy; HCP, healthcare professional; imARs, immune-mediated adverse reactions; NSCLC, non-small cell lung cancer; OS, overall survival.
Patient Resources
Available in 13 languages
IMFINZI & Me App video
NSCLC
ES-SCLC
Watch this video to learn more about how the IMFINZI & Me App can help support your patients.
IMFINZI & Me App Brochure
NSCLC
ES-SCLC
Download the brochure for patients to learn how to join the IMFINZI & Me App.
Patient Information and Side
Effects Brochure
NSCLC
A guide for patients with important information about Imfinzi treatment and how to recognize possible side effects.
Caregiver Brochure
NSCLC
Guidance for Imfinzi patients’ loved ones to help them through the treatment process.
Side Effects Tracker
NSCLC
A tool for patients to track any side effects they may experience during Imfinzi treatment.
Tell your patients about the community on the IMFINZI & Me app. Through the app, patients and caregivers can connect with each other for support, access to education programs, as well as helpful tips and reminders.
References:
1.Imfinzi Product Monograph. AstraZeneca Canada Inc. January 17, 2025.
2.Antonia SJ, et al. Overall Survival with Durvalumab after chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342-2350.
3.Spigel DR, et al. Five-Year Survival Outcomes from the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40(12):1301-1311.